维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

14篇 您的检索式：作者名="MT Butt"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: Impact of bilharziasis and fibrosis stage显示文摘AIM: To evaluate pegylated interferon alpha2a (PegIFN- α2a) in Egyptian patients with HCV genotype 4, and the impact of pretreatment viral load, co-existent bilharziasis and histological liver changes on response rate. METHODS: A total of 73 na?ve patients (61 with history of bilharziasis) with compensated chronic HCV genotype 4 were enrolled into: group A (38 patients) who received 180 mg PegIFN-alpha2a subcutaneously once weekly for a year and group B (35 patients) received IFN alpha-2a 3 MU 3 times weekly. Ribavirin was added to each regimen at a dose of 1200 mg. Patients were followed for 72 wk and sustained response was assessed. RESULTS: Significant improvement in both end of treatment response (ETR) (P < 0.002) and sustained response (SR) (P < 0.05) was noted with pegylated interferon, where ETR was achieved in 29 (76.3%) and 14 patients (40%) in both groups respectively, and 25 patients in group A (65.8%) and 9 (25.7%) in group B could retain negative viraemia by the end of follow up period. Sustained virological response (SVR) showed a significant negative correlation with age and positive correlation with pretreatment inflammation in patients receiving PegIFN. Viral clearance after 3 mo of therapy was associated with high incidence of ETR and SR (P < 0.001), but without significant difference between both forms of interferon. Significant improvement in response was achieved in patients with high grade fibrosis (grade 3 and 4) with PegIFN-α2a, where SR was seen in 5 out of 13 patients in group A, but none in group B. There was no significant difference in response betweenbilharzial and non-bilharzial patients in both groups. In terms of safety and tolerability, neutropenia was the predominant side effect; both drugs were comparable. CONCLUSION: PegIFN-α2a combined with ribavirin results in improvement in sustained response in HCV genotype 4, irrespective of history of bilharzial infestation.	MF Derbala SR Al Kaabi NZ El Dweik F Pasic MT Butt R Yakoob A Al-Marri AM Amer N Morad A Bener	2006	World Journal of Gastroenterology2006，12，35：	3
	2	No follow-up after positive newborn screening: medical neglect?显示文摘	Merrick MT Butt SM Jent JF	2010	Child Maltreat2010，15，4：	1
	3	Green tea: nature's defense against malignancies显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	4	Clinical assessment incor- porating a person genome显示文摘	Ashley EA Butte AJ Wheeler MT	2010	Lancet2010，375，9725：	1
	5	Coffee and its consumption; benefits and risks显示文摘	Butt MS Sultan MT	2011	Crit Rev Food Sci Nutr2011，51，4：	1
	6	Green tea: natures defense against ma- lignancies显示文摘	BUTT MS SULTAN MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	7	Green tea: nature's defense against malignancies 显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	8	Green tea: nature's defense against malignancies 显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	9	Green tea:nature′s defense against malignancies显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	10	Green tea:nature's defense against malignancies显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	11	Six-month continuous intraputamenal infusion toxicity study of recombinant methionyl human glial cell line-derived neurotrophic factor (r-metHuGDNF) in rhesus monkeys显示文摘	Hovland DN Jr Boyd RB Butt MT	2007	Toxicol Pathol2007，35，7：	1
	12	Green tea: nature's defense against malig- nancies 显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	13	Green tea:nature's defense against malignancies显示文摘	Butt MS Sultan MT	2009	Crit Rev Food Sci Nutr2009，49，5：	1
	14	Coffee and its consumption:benefitsand risks显示文摘	Butt MS Sultan MT	2011	Crit Rev Food Sci Nutr2011，51，4：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费